biopharmaceutical development

BenevolentAI Embarks on Strategic Overhaul to Realign with Founding TechBio Mission

4 months ago talkbio0Tagged Artificial Intelligence, BenevolentAI, biopharmaceutical development, Drug Discovery, Kenneth, Mulvany, Strategic Overhaul, TechBio mission

BenevolentAI, strategic overhaul, TechBio mission, artificial intelligence, biopharmaceutical development, drug discovery, Kenneth Mulvany

Viridian Therapeutics’ Veligrotug Achieves Positive Topline Results in Phase 3 THRIVE Clinical Trial for Thyroid Eye Disease

8 months ago talkbio0Tagged Antibodies, biopharmaceutical development, Clinical Trials, Phase 3, Success, Thrive, Thyroid associated opthalmopathies, Veligrotug, VRDN-001

Veligrotug (VRDN-001), Thyroid Eye Disease (TED), Phase 3 THRIVE Clinical Trial, Anti-IGF-1R Antibody, Clinical Trial Success, Biopharmaceutical Development

Navigating the Complexities of Adding Rare Disease Products to Your Company’s Portfolio

10 months ago talkbio0Tagged Access, biopharmaceutical development, commercialization, Contract Strategy, Identification (Psychology), Market, Rare disease products, regulatory incentives, Technology, value-based

Rare disease products, biopharmaceutical development, commercialization, market access, patient identification, payer contract strategy, value-based contracting, regulatory incentives, emerging technology.